RxDoctor Payments DataLook up a doctor →

Lisa Ostrowski

Physician Assistant · Arlington, TXNPI 1881853786

Payments from drug & device makers

$47,006in general payments, 2019–2025

Across 1,235 payments — averaging $38.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biofrontera Inc.$23K
  • AbbVie$3K
  • UCB, Inc.$3K
  • Johnson & Johnson$2K
  • Sun Pharmaceutical Industries Inc.$2K
  • Dermavant Sciences, Inc.$2K
  • plus $12K from 26 others

What the payments were for

  • Royalty or licence$22,50048%
  • Consulting fees$2,3255%
  • Speaking & faculty fees$2,3535%
  • Travel & lodging$300%
  • Food & beverage$19,36441%
  • Education$4331%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,006 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$269,081
Medicare patients
417
Services billed
35,938

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab76$301,293
OtezlaApremilast24$123,771
Humira(Cf) PenAdalimumab16$106,191
EnbrelEtanercept14$102,230
RinvoqUpadacitinib13$78,710
AdbryTralokinumab-Ldrm14$53,978
VtamaTapinarof17$22,868
ZoryveRoflumilast13$10,724
Imiquimod169$5,555
Clobetasol Propionate104$4,709
Tretinoin21$2,095
Minoxidil192$1,835
Ketoconazole65$1,425
Fluorouracil22$1,348
Doxycycline Hyclate79$1,237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Enbrel$1,056$226,00138 claims
AbbVieRinvoq$3,244$78,71013 claims
LEO Pharma Inc.Adbry$612$53,97814 claims
Dermavant Sciences, Inc.Vtama$1,799$22,86817 claims
Arcutis Biotherapeutics, Inc.Zoryve$805$10,72413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →